{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.10 vs. cons $1.08",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$1.73B vs. cons $1.72B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic revenue growth (incl. contingents)",
      "prediction": "IN-LINE",
      "answer": "pred ~1.5% vs. cons ~1.5%",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "2H26 organic growth ramp (upper-bound framing)",
      "prediction": "UNCHANGED",
      "answer": "guide ~2.0-2.5% vs. cons ~2.5% (2H26)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 organic growth",
      "prediction": "LOWER",
      "answer": "guide ~1.5% vs. cons ~2.0% (FY26)",
      "confidence": "LOW"
    },
    {
      "kpi": "FY26 contingent commissions",
      "prediction": "BETTER",
      "answer": "guide ~$270M vs. cons ~$258M (FY26)",
      "confidence": "LOW"
    },
    {
      "kpi": "Adjusted EBITDAC margin",
      "prediction": "UNCHANGED",
      "answer": "guide ~36.8% vs. cons ~36.7% (Q2/FY26)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 0.5,
  "day1_confidence": "LOW",
  "day5_residual_pct": -1.5,
  "day5_path": "FADE",
  "day5_rationale": "EPS likely beats on strong contingents and Accession scale, but the core-organic 'whole ballgame' stays soft as CAT property rates fall (-15-35%) into the seasonally property-heavy Q2 and the pharmacy-model/litigation drags persist. After a ~20% run off the May lows into the print, the bar is high and much of the 2H re-acceleration hope is already priced. Even on a headline beat, the out-period math (continued property softness, ~2.5% capped organic) prompts sell-side to trim 2H/FY organic and revenue estimates, so an initial modest pop fades over the week.",
  "day5_confidence": "LOW"
}